Mereo BioPharma Group plc (MREO) Form 8-K — Aug 11, 2026
Mereo BioPharma entered into an Option and License Agreement with Sentynl Therapeutics, a U.S. rare-disease biopharma and wholly-owned subsidiary of Zydus Lifesciences, granting Sentynl U.S. commercial and global manufacturing rights to alvelestat for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo retains commercial rights in the rest of the world and will lead the global Phase 3 study and regulatory interactions until the study is completed.
Key figures
- Deal Value Usd
- up to $475 million total potential ($40 million upfront and R&D payments plus up to $435 million in milestones)
- Royalty Terms
- double-digit tiered royalties on U.S. net sales of alvelestat
- Non Refundable Option Fee
- amount not disclosed
- Potential Phase3 Initiation
- early 2027
- Potential Milestone Payments
- 435000000
- Us Aatd Ld Prevalence Estimate
- 50,000-80,000 individuals
- Patients In Prior Clinical Trials
- over 1,000
- Upfront And Rd Payments On Option Exercise
- 40000000
Price after filing
Close on the filing date to close N calendar days later (from $0.30). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.